

Eric M Ruderman

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3253428/publications.pdf>

Version: 2024-02-01

58
papers

2,444
citations

411340

20
h-index

242451

47
g-index

60
all docs

60
docs citations

60
times ranked

2941
citing authors

#	ARTICLE	IF	CITATIONS
1	Low-dose Methotrexate Therapy Does Not Affect Semen Parameters and Sperm DNA. Inflammatory Bowel Diseases, 2022, 28, 1012-1018.	0.9	8
2	A Road Map of the Axial Spondyloarthritis Continuum. Mayo Clinic Proceedings, 2022, 97, 134-145.	1.4	5
3	Safety Profile of Upadacitinib up to 3 Years in Psoriatic Arthritis: An Integrated Analysis of Two Pivotal Phase 3 Trials. Rheumatology and Therapy, 2022, 9, 521-539.	1.1	18
4	Evaluation of an Intervention to Support <sc>Patientâ€Rheumatologist</sc> Conversations About Escalating Treatment in Patients with Rheumatoid Arthritis: A <sc>Proofâ€ofâ€Principle</sc> Study. ACR Open Rheumatology, 2022, 4, 279-287.	0.9	1
5	Upadacitinib as monotherapy and in combination with non-biologic disease-modifying antirheumatic drugs for psoriatic arthritis. Rheumatology, 2022, 61, 3257-3268.	0.9	11
6	Any Given Monday: Association Between Desk Rejections and Weekend Manuscript Submissions to Rheumatology Journals. Journal of Rheumatology, 2022, 49, 652-653.	1.0	2
7	Updates in the Treatment of Rheumatoid Arthritis. Current Treatment Options in Rheumatology, 2021, 7, 99.	0.6	1
8	Brutonâ€™s Tyrosine Kinase Inhibition for the Treatment of Rheumatoid Arthritis. ImmunoTargets and Therapy, 2021, Volume 10, 333-342.	2.7	17
9	Patient and Rheumatologist Perspectives Regarding Challenges to Achieving Optimal Disease Control in Rheumatoid Arthritis. Arthritis Care and Research, 2020, 72, 933-941.	1.5	9
10	Efficacy and Safety of Ixekizumab with or Without Methotrexate in Biologic-Naïve Patients with Psoriatic Arthritis: 52-Week Results from SPIRIT-H2H Study. Rheumatology and Therapy, 2020, 7, 1021-1035.	1.1	21
11	The Quality of Randomized Controlled Trials in High-impact Rheumatology Journals, 1998â€“2018. Journal of Rheumatology, 2020, 47, 1446-1449.	1.0	5
12	Outreach to Promote Management of Cardiovascular Risk in Primary Care Among Patients With Rheumatoid Arthritis Seen in Rheumatology Practice. ACR Open Rheumatology, 2020, 2, 131-137.	0.9	2
13	Learning from Adversity: Lessons from the COVID-19 Crisis. Journal of Rheumatology, 2020, 47, 791-792.	1.0	7
14	OPO294â€™...TRANSCRIPTIONAL PROFILING OF RA PATIENTS SYNOVIAL TISSUE REVEALS TARGETS FOR PRECISION MEDICINE. , 2019, , .		0
15	Transcriptional Profiling of Synovial Macrophages Using Minimally Invasive Ultrasoundâ€Guided Synovial Biopsies in Rheumatoid Arthritis. Arthritis and Rheumatology, 2018, 70, 841-854.	2.9	44
16	Clusterâ€Randomized Trial of a Behavioral Intervention to Incorporate a Treatâ€toâ€Target Approach to Care of <sc>US</sc> Patients With Rheumatoid Arthritis. Arthritis Care and Research, 2018, 70, 379-387.	1.5	30
17	Standardizing and personalizing the treat to target (T2T) approach for rheumatoid arthritis using the Patient-Reported Outcomes Measurement Information System (PROMIS): baseline findings on patient-centered treatment priorities. Clinical Rheumatology, 2017, 36, 1729-1736.	1.0	29
18	Fungal Infections of Bones and Joints. , 2017, , 1918-1928.e3.		2

#	ARTICLE	IF	CITATIONS
19	Nonradiographic axial spondyloarthritis: clinical and therapeutic relevance. <i>Arthritis Research and Therapy</i> , 2017, 19, 286.	1.6	18
20	Mycobacterial Infections of Bones and Joints. , 2017, , 1905-1917.		1
21	Willie Sutton Was Right: It's Time to Turn to the Synovium to Drive Rheumatoid Arthritis Therapy. <i>Journal of Rheumatology</i> , 2016, 43, 2089-2091.	1.0	2
22	A Multifaceted Intervention to Improve Influenza, Pneumococcal, and Herpes Zoster Vaccination among Patients with Rheumatoid Arthritis. <i>Journal of Rheumatology</i> , 2016, 43, 1030-1037.	1.0	25
23	Diagnosis and evaluation of psoriasis and psoriatic arthritis. , 2016, , 27-42.		0
24	Understanding vaccination rates and attitudes among patients with rheumatoid arthritis. <i>American Journal of Managed Care</i> , 2016, 22, 161-7.	0.8	16
25	Influence of Continuing Medical Education on Rheumatologists' Performance on National Quality Measures for Rheumatoid Arthritis. <i>Rheumatology and Therapy</i> , 2015, 2, 141-151.	1.1	6
26	IL-6 inhibition in RA—does it all over again?. <i>Nature Reviews Rheumatology</i> , 2015, 11, 321-322.	3.5	5
27	Of Mice and Men: Defining the Role of Interleukin 17 in Rheumatoid Arthritis. <i>Journal of Rheumatology</i> , 2015, 42, 1069-1071.	1.0	1
28	Natural History, Prognosis, and Socioeconomic Aspects of Psoriatic Arthritis. <i>Rheumatic Disease Clinics of North America</i> , 2015, 41, 581-591.	0.8	20
29	Current Practice Patterns and Educational Needs of Rheumatologists Who Manage Patients with Rheumatoid Arthritis. <i>Rheumatology and Therapy</i> , 2014, 1, 31-44.	1.1	8
30	Prevalence of Axial Spondyloarthritis in United States Rheumatology Practices: Assessment of SpondyloArthritis International Society Criteria Versus Rheumatology Expert Clinical Diagnosis. <i>Arthritis Care and Research</i> , 2013, 65, 1299-1306.	1.5	78
31	Mycobacterial Infections of Bones and Joints. , 2013, , 1829-1840.		0
32	Fungal Infections of Bones and Joints. , 2013, , 1841-1850.		1
33	Safety and efficacy of biologics, and the future direction of rheumatoid arthritis therapy. <i>International Journal of Clinical Rheumatology</i> , 2012, 7, 473-474.	0.3	0
34	Overview of safety of non-biologic and biologic DMARDs. <i>Rheumatology</i> , 2012, 51, vi37-vi43.	0.9	107
35	Incorporating the Treat-to-Target Concept in Rheumatoid Arthritis. <i>Journal of Managed Care Pharmacy</i> , 2012, 18, 1-18.	2.2	7
36	More than just B-cell inhibition. <i>Arthritis Research and Therapy</i> , 2011, 13, 125.	1.6	22

#	ARTICLE	IF	CITATIONS
37	Safety of biologic therapy in rheumatoid arthritis. <i>Nature Reviews Rheumatology</i> , 2011, 7, 639-652.	3.5	73
38	Increasing physical activity in patients with arthritis: a tailored health promotion program. <i>Chronic Illness</i> , 2010, 6, 272-281.	0.6	16
39	Do we really need five TNF antagonists?. <i>Rheumatology</i> , 2010, 49, 1028-1029.	0.9	1
40	Novel TNF antagonists for the treatment of rheumatoid arthritis. <i>Expert Opinion on Investigational Drugs</i> , 2010, 19, 105-115.	1.9	15
41	The CDK domain of p21 is a suppressor of IL-1 β -mediated inflammation in activated macrophages. <i>European Journal of Immunology</i> , 2009, 39, 820-825.	1.6	59
42	Intracellular signal pathways: Potential for therapies. <i>Current Rheumatology Reports</i> , 2009, 11, 378-385.	2.1	58
43	Natural History, Prognosis, and Socioeconomic Aspects of Psoriatic Arthritis. , 2007, , 29-36.		0
44	Adalimumab in Psoriatic Arthritis. <i>Drugs</i> , 2006, 66, 1497-1499.	4.9	0
45	The treatment of psoriasis and psoriatic arthritis: An interdisciplinary approach. <i>Journal of the American Academy of Dermatology</i> , 2006, 54, S85-S91.	0.6	32
46	Drug Insight: abatacept for the treatment of rheumatoid arthritis. <i>Nature Clinical Practice Rheumatology</i> , 2006, 2, 654-660.	3.2	27
47	Systematic review of studies of productivity loss due to rheumatoid arthritis. <i>Occupational Medicine</i> , 2006, 56, 18-27.	0.8	239
48	Adalimumab for the treatment of patients with moderately to severely active psoriatic arthritis: Results of a double-blind, randomized, placebo-controlled trial. <i>Arthritis and Rheumatism</i> , 2005, 52, 3279-3289.	6.7	828
49	Treatment advances in psoriatic arthritis. <i>Current Rheumatology Reports</i> , 2005, 7, 313-318.	2.1	1
50	The evolving clinical profile of abatacept (CTLA4-Ig): a novel co-stimulatory modulator for the treatment of rheumatoid arthritis. <i>Arthritis Research</i> , 2005, 7, S21.	2.0	80
51	Current and Future Pharmaceutical Therapy for Rheumatoid Arthritis. <i>Current Pharmaceutical Design</i> , 2005, 11, 671-684.	0.9	12
52	Assuming cost is not an issue, should every patient with RA receive biologic therapy?. <i>Internal Medicine News</i> , 2005, 38, 13.	0.0	0
53	Psoriatic arthritis: prevalence, diagnosis, and review of therapy for the dermatologist. <i>Dermatologic Clinics</i> , 2004, 22, 477-486.	1.0	33
54	Damage control in rheumatoid arthritis. <i>Postgraduate Medicine</i> , 2004, 116, 14-24.	0.9	5

#	ARTICLE	IF	CITATIONS
55	Evaluation and management of psoriatic arthritis: the role of biologic therapy. <i>Journal of the American Academy of Dermatology</i> , 2003, 49, 125-132.	0.6	29
56	Concomitant Leflunomide Therapy in Patients with Active Rheumatoid Arthritis despite Stable Doses of Methotrexate. <i>Annals of Internal Medicine</i> , 2002, 137, 726.	2.0	287
57	Synovial tissue response to treatment with campath-1h. <i>Arthritis and Rheumatism</i> , 1995, 38, 254-258.	6.7	50
58	Treatment of stiff-man syndrome with intravenous immune globulin. <i>Arthritis and Rheumatism</i> , 1994, 37, 915-918.	6.7	69